Pharmacological Issues in the Treatment of Tuberculosis
- 1 December 2001
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 953b (1) , 157-164
Abstract
Abstract: A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.Keywords
This publication has 22 references indexed in Scilit:
- Tuberculosis Drug Serum LevelsClinical Infectious Diseases, 2001
- Tuberculosis Recurrence: Multivariate Analysis of Serum Levels of Tuberculosis Drugs, Human Immunodeficiency Virus Status, and Other Risk FactorsClinical Infectious Diseases, 2001
- Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin AntibacterialsClinical Pharmacokinetics, 2001
- Therapeutic Implications of Drug Interactions in the Treatment of Human Immunodeficiency Virus‐Related TuberculosisClinical Infectious Diseases, 1999
- Once Daily Aminoglycoside TherapyClinical Pharmacokinetics, 1999
- The Pharmacodynamics of β‐LactamsClinical Infectious Diseases, 1998
- Methodological Issues in Pharmacokinetic-Pharmacodynamic ModellingClinical Pharmacokinetics, 1998
- Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There?Clinical Infectious Diseases, 1994
- A Critical Reevaluation of the "Therapeutic Range" of AminoglycosidesClinical Infectious Diseases, 1992
- Why Monitor Serum Levels of Gentamicin?Clinical Pharmacokinetics, 1978